Sugi Predict

Sugi Predict / Compounds / SCHEMBL2411177

SCHEMBL2411177

SCHEMBL2411177

COC(=O)CNC1CCCCC1

nearest known ligand 0.62

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 4/20 0.62
▸ NPSR1 Q6W5P4 1/20 0.48
▸ KDM4E B2RXH2 3/20 0.45
▸ POLB P06746 1/20 0.45
▸ DPP7 Q9UHL4 5/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ DPP4 P27487 6/20 0.42
▸ FAP Q12884 4/20 0.42
▸ EPHX1 P07099 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.41
▸ HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18845118 1.00 EPHX2 (0.62) EPHX2NPSR1KDM4EPOLBDPP7
Hydrochloric Acid SCHEMBL75462 0.98 EPHX2 (0.61) EPHX2NPSR1KDM4EPOLBDPP7
SCHEMBL1977433 0.98 EPHX2 (0.59) EPHX2NPSR1KDM4EPOLBDPP7
Hydrochloric Acid SCHEMBL6871695 0.96 EPHX2 (0.58) EPHX2NPSR1KDM4EPOLBDPP7
Hydrochloric Acid SCHEMBL7131992 0.94 EPHX2 (0.57) EPHX2NPSR1KDM4EPOLBDPP7
SCHEMBL7440501 0.94 EPHX2 (0.55) EPHX2NPSR1KDM4EPOLBDPP7
SCHEMBL4450020 0.89 — —
Hydrochloric Acid SCHEMBL7134822 0.88 EPHX2 (0.51) EPHX2NPSR1KDM4EPOLBDPP7
Hydrochloric Acid SCHEMBL76321 0.87 EPHX2 (0.47) EPHX2KDM4EDPP7MEN1KMT2A
SCHEMBL1320792 0.82 KDM4E (0.56) EPHX2NPSR1KDM4EPOLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3998260-B1 SGC STIMULATORS CYCLERION THERAPEUTICS INC (US) 2023-11-01 — — EP disclosed
CN-109369635-B Compound or pharmaceutically acceptable salt thereof, application thereof and pharmaceutical composition 赛克里翁治疗有限公司 2023-06-30 — — CN disclosed
US-20230106002-A1 sGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. 2023-04-06 — — US disclosed
CN-109384778-B Use of a compound or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a disease, health condition or disorder 赛克里翁治疗有限公司 2022-12-13 — — CN disclosed
CN-110016020-B Compound or pharmaceutically acceptable salt thereof, application and pharmaceutical composition thereof 赛克里翁治疗有限公司 2022-07-26 — — CN disclosed
EP-3998260-A1 SGC STIMULATORS Cyclerion Therapeutics, Inc. (US) 2022-05-18 — — EP disclosed
US-11142543-B2 Antidepressant compound and preparation method and application thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2021-10-12 — — US disclosed
US-11111245-B2 Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents AUCENTRA THERAPEUTICS PTY LTD (AU) 2021-09-07 — — US disclosed
US-20200385418-A1 ANTIDEPRESSANT COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2020-12-10 — — US disclosed
US-20200231586-A1 DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO[1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS AUCENTRA THERAPEUTICS PTY LTD (AU) 2020-07-23 — — US disclosed
US-5849510-A Factor Xa inhibitors SELECTIDE CORPORATION (US) 1998-12-15 — — US disclosed
WO-1998047876-A1 HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS AKZO NOBEL N.V. (NL) 1998-10-29 — — WO disclosed
CN-1147261-A Factor Xa inhibitors SELECTIDE CORP (US) 1997-04-09 — — CN disclosed
EP-0758341-A1 FACTOR Xa INHIBITORS SELECTIDE CORPORATION (US) 1997-02-19 — — EP disclosed
WO-1995029189-A1 FACTOR Xa INHIBITORS SELECTIDE CORPORATION (US) 1995-11-02 — — WO disclosed
WO-1995008550-A1 ENDOTHELIN ANTAGONISTS ABBOTT LABORATORIES (US) 1995-03-30 — — WO disclosed
EP-0640594-A1 Hydantoin derivative as metalloprotease inhibitor FUJIREBIO INC. (JP) 1995-03-01 — — EP disclosed
US-4775674-A CARDIOTONIC AGENTS BRISTOL-MYERS COMPANY (US) 1988-10-04 — — US disclosed
US-4690925-A ANTITHROMBOTIC ACTIVITY, CARDIOTONIC AGENTS SYNTEX (U.S.A.) INC. (US) 1987-09-01 — — US disclosed
EP-0153152-A2 (2-Oxo-1,2,3,5-tetrahydroimidazo-/2,1-b/quinnazolinyl)-oxyalkylamides, their preparation, compositions containing them and their use in making medicaments SYNTEX (U.S.A.) INC. (US) 1985-08-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230106002-A1 sGC STIMULATORS PTGIS, CGAS, GUCY1A1 EPHX2 2422/4885NPSR1 1663/4885KDM4E 2350/4885
US-20200231586-A1 DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO[1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS CDK2, CDKL1, CDKL2 EPHX2 3586/4885NPSR1 3298/4885KDM4E 1080/4885
US-11142543-B2 Antidepressant compound and preparation method and application thereof TPH1, BDNF, CRH EPHX2 1304/4885NPSR1 73/4885KDM4E 1171/4885
US-20200385418-A1 ANTIDEPRESSANT COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF TPH1, BDNF, CRH EPHX2 1304/4885NPSR1 73/4885KDM4E 1171/4885
US-11111245-B2 Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents CDK2, CDKL1, CDKL2 EPHX2 3586/4885NPSR1 3298/4885KDM4E 1080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.